selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.The company is well positioned to expand its range of class-leading ion channelblockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.

Therapeutics

Biotechnology

selectION

Antonius Schuh

Mark C. Wiggins

Elizabeth Anderson

Andreas Klostermann

Stephen Zaniboni

The Leadership Team at selectION is responsible for setting the strategic vision and direction of the company, guiding the development of innovative ion channel blockers. This team oversees key operational areas including finance, research and development, and corporate governance to ensure alignment with the company’s mission of advancing therapeutic solutions for TEM-driven diseases and beyond. Their expertise drives selectION's growth and success in the competitive biotechnology landscape.

Leadership Team

Scientific Advisors

Leadership Team

About

Team members

Other teams at selectION

Scientific Advisors